secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001193125-26-154009
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics to merge with Obsidian in all-stock deal backed by $350M PIPE
--------------------------------------------------------------------------------

- Galera and Obsidian to merge under new parent; Galera shareholders get ~1.8% of combined co plus CVRs.
- Obsidian shareholders get ~53.2%; $350M PIPE investors get ~45% of combined company.
- Galera valued at $13.8M (net cash $1.8M), Obsidian at $413.5M; closing conditions include S-4 effectiveness.
- Galera legacy assets (tilarganine, avasopasem, rucosopasem) subject to CVR payout to Galera common holders.
- Insider support: 51.1% Galera holders and 62.8% Obsidian holders agree to vote in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/0001193125-26-154009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/d124753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-154009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer